265 related articles for article (PubMed ID: 27144514)
1. Omalizumab treatment in asthma-COPD overlap syndrome.
Tat TS; Cilli A
J Asthma; 2016 Dec; 53(10):1048-50. PubMed ID: 27144514
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.
Yalcin AD; Celik B; Yalcin AN
Immunopharmacol Immunotoxicol; 2016 Jun; 38(3):253-6. PubMed ID: 27121601
[TBL] [Abstract][Full Text] [Related]
3. Should omalizumab be used in severe asthma/COPD overlap?
Sposato B; Scalese M; Milanese M; Masieri S; Cavaliere C; Ricci A; Paggiaro P
J Biol Regul Homeost Agents; 2018; 32(4):755-761. PubMed ID: 30043557
[TBL] [Abstract][Full Text] [Related]
4. Treatment trends in patients with asthma-COPD overlap syndrome in a COPD cohort: findings from a real-world survey.
Ding B; Small M
Int J Chron Obstruct Pulmon Dis; 2017; 12():1753-1763. PubMed ID: 28670116
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO.
Hanania NA; Chipps BE; Griffin NM; Yoo B; Iqbal A; Casale TB
J Allergy Clin Immunol; 2019 Apr; 143(4):1629-1633.e2. PubMed ID: 30576755
[No Abstract] [Full Text] [Related]
6. Clinical, physiological, and radiological features of asthma-chronic obstructive pulmonary disease overlap syndrome.
Suzuki T; Tada Y; Kawata N; Matsuura Y; Ikari J; Kasahara Y; Tatsumi K
Int J Chron Obstruct Pulmon Dis; 2015; 10():947-54. PubMed ID: 26028967
[TBL] [Abstract][Full Text] [Related]
7. Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence.
Hines KL; Peebles RS
Curr Allergy Asthma Rep; 2017 Mar; 17(3):15. PubMed ID: 28283854
[TBL] [Abstract][Full Text] [Related]
8. [OMALIZUMAB RESCUED A ASTHMA-COPD OVERLAP SYNDROME PATIENT FROM A STATUS ASTHMATICS UNDER THE ICU MANAGEMENT].
Gamo S; Iijima H; Seki Y; Horaguchi R; Suda Y; Shindoh Y
Arerugi; 2016 Jul; 65(7):937-41. PubMed ID: 27545060
[TBL] [Abstract][Full Text] [Related]
9. Can Xolair Be Used in Nonallergic Asthmatic?
Ledford DK; Casale TB
J Allergy Clin Immunol Pract; 2018; 6(6):2170. PubMed ID: 30390909
[No Abstract] [Full Text] [Related]
10. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
[TBL] [Abstract][Full Text] [Related]
11. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
[TBL] [Abstract][Full Text] [Related]
12. Relationship between Fractional Exhaled Nitric Oxide Level and Efficacy of Inhaled Corticosteroid in Asthma-COPD Overlap Syndrome Patients with Different Disease Severity.
Feng JX; Lin Y; Lin J; He SS; Chen MF; Wu XM; Xu YZ
J Korean Med Sci; 2017 Mar; 32(3):439-447. PubMed ID: 28145647
[TBL] [Abstract][Full Text] [Related]
13. Long-term course of serum total and free IgE levels in severe asthma patients treated with omalizumab.
Gon Y; Ito R; Maruoka S; Mizumura K; Kozu Y; Hiranuma H; Iida Y; Hikichi M; Shikano S; Hashimoto S
Allergol Int; 2018 Apr; 67(2):283-285. PubMed ID: 28927962
[No Abstract] [Full Text] [Related]
14. Phenotype of asthma-chronic obstructive pulmonary disease overlap syndrome.
Rhee CK
Korean J Intern Med; 2015 Jul; 30(4):443-9. PubMed ID: 26161009
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.
Ishiura Y; Fujimura M; Shiba Y; Ohkura N; Hara J; Kasahara K
Pulm Pharmacol Ther; 2015 Dec; 35():28-33. PubMed ID: 26497109
[TBL] [Abstract][Full Text] [Related]
16. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab therapy in a 13-year-old boy with severe persistent asthma and concomitant eosinophilic esophagitis.
Arasi S; Costa S; Magazzù G; Ieni A; Crisafulli G; Caminiti L; Chiera F; Vaccaro M; Del Giudice MM; Pajno GB
Ital J Pediatr; 2016 Mar; 42():32. PubMed ID: 27000314
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
[TBL] [Abstract][Full Text] [Related]
20. High serum free IL-18 is associated with decreased omalizumab efficacy: findings from a 2-year omalizumab treatment study.
Morimoto C; Matsumoto H; Tajiri T; Gon Y; Ito R; Hashimoto S; Suzukawa M; Ohta K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Kanemitsu Y; Nagasaki T; Izuhara Y; Niimi A; Hirai T
J Asthma; 2021 Sep; 58(9):1133-1142. PubMed ID: 32375555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
